Biotech · Public company · Los Angeles, CA, US
Armata Pharmaceuticals, Inc.
Ticker ARMP · SEC CIK 0000921114
Track this companyFree. Adds Armata Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials100 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline8
- AP-PA02Phase 2 · Cystic FibrosisClinicalTrials.gov · fetched Nov 12, 2026
- AP-PA02Phase 2 · Non-cystic Fibrosis BronchiectasisClinicalTrials.gov · fetched Nov 12, 2026
- AP-SA02Phase 2 · BacteremiaClinicalTrials.gov · fetched Nov 12, 2026
- C16G2Phase 2 · Dental CariesClinicalTrials.gov · fetched Nov 12, 2026
- C16G2 GelPhase 2 · Dental CariesClinicalTrials.gov · fetched Nov 12, 2026
- C16G2 RinsePhase 2 · Dental CariesClinicalTrials.gov · fetched Nov 12, 2026
- C16G2 StripPhase 2 · Dental CariesClinicalTrials.gov · fetched Nov 12, 2026
- C16G2 VarnishPhase 2 · Dental CariesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa InfectionPHASE2 · COMPLETED · started Jan 10, 2023ClinicalTrials.gov NCT05616221 · fetched Nov 12, 2026
- Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus BacteremiaPHASE1_PHASE2 · COMPLETED · started Apr 26, 2022ClinicalTrials.gov NCT05184764 · fetched Nov 12, 2026
- Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic FibrosisPHASE1_PHASE2 · COMPLETED · started Dec 22, 2020ClinicalTrials.gov NCT04596319 · fetched Nov 12, 2026
- A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult SubjectsPHASE2 · COMPLETED · started Jul 7, 2017ClinicalTrials.gov NCT03196219 · fetched Nov 12, 2026
- A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip ApplicationPHASE2 · COMPLETED · started Feb 9, 2017ClinicalTrials.gov NCT03052842 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental SubjectsPHASE2 · COMPLETED · started Jan 27, 2017ClinicalTrials.gov NCT03004365 · fetched Nov 12, 2026
- Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental SubjectsPHASE2 · COMPLETED · started Nov 1, 2015ClinicalTrials.gov NCT02594254 · fetched Nov 12, 2026
- Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental SubjectsPHASE2 · COMPLETED · started Jul 1, 2015ClinicalTrials.gov NCT02509845 · fetched Nov 12, 2026
- Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel DosesPHASE2 · COMPLETED · started Oct 1, 2014ClinicalTrials.gov NCT02254993 · fetched Nov 12, 2026
- Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy AdultsPHASE2 · COMPLETED · started Feb 1, 2014ClinicalTrials.gov NCT02044081 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Sep 23, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 14, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 20, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 20, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 13, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Jun 24, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 16, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026